Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment

To evaluate visual and anatomic outcomes after intravitreal aflibercept injection (IAI) versus laser in diabetic macular edema (DME) patients with and without prior anti-vascular endothelial growth factor (VEGF) treatment for DME.Post hoc analysis of eyes from 2 similarly designed, phase 3 trials, VISTA and VIVID.Patients (eyes) with DME with central involvement from VISTA (n = 461) and VIVID (n = 404).Eyes received IAI 2 mg every 4 weeks (2q4),...